Aneurysmal Subarachnoid Hemorrhage Market

Market Overview:

The 7 major aneurysmal subarachnoid hemorrhage markets reached a value of US$ 245.9 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 331.9 Million by 2034, exhibiting a growth rate (CAGR) of 2.76% during 2024-2034.

The aneurysmal subarachnoid hemorrhage market has been comprehensively analyzed in IMARC's new report titled "Aneurysmal Subarachnoid Hemorrhage Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Aneurysmal subarachnoid hemorrhage refers to a critical medical condition characterized by bleeding into the brain's surrounding region, known as the subarachnoid space. This often occurs due to the rupture of an intracranial aneurysm, a weakened and bulging blood vessel in the brain. The sudden release of blood leads to increased pressure on the brain and can result in severe neurological complications. The symptoms of the disorder can be abrupt and intense, including a sudden and severe headache. Individuals suffering from this illness might also experience nausea, vomiting, sensitivity to light (photophobia), neck stiffness, etc. In severe cases, the ailment can lead to loss of consciousness, confusion, and even coma. The diagnosis mainly involves a combination of medical history assessment, physical examination, and imaging techniques. The healthcare provider will also conduct a lumbar puncture to analyze the cerebrospinal fluid (CSF) for the presence of blood and to assess the CSF pressure.

The increasing incidence of several associated risk factors, including high blood pressure, excessive alcohol consumption, illicit drug use, smoking, family history, genetic alterations, etc., is primarily driving the aneurysmal subarachnoid hemorrhage market. In addition to this, the inflating utilization of efficient treatments, such as endovascular coiling procedures and neurosurgical clipping techniques, to stop the bleeding and prevent further complications in individuals suffering from the illness is creating a positive outlook for the market. Moreover, the widespread adoption of rehabilitation therapies, as they aid in cognitive recovery, restore physical abilities, and support emotional healing, is also bolstering the market growth. Apart from this, the growing demand for advanced imaging techniques like computed tomography (CT) angiography and magnetic resonance imaging (MRI), which provide detailed visuals of the brain's vascular structures, is acting as another significant growth-inducing factor. Additionally, the rising application of precision medicine, tailoring treatments based on individual patient profiles and genetic susceptibilities, is also augmenting the market growth. Furthermore, the emerging popularity of non-invasive interventions, such as neuroprotective medications and neuromodulation techniques, since they minimize the neurological deficits associated with this disorder and improve the quality of life, is expected to drive the aneurysmal subarachnoid hemorrhage market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the aneurysmal subarachnoid hemorrhage market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for aneurysmal subarachnoid hemorrhage and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the aneurysmal subarachnoid hemorrhage market in any manner.

Time Period of the Study

•  Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the aneurysmal subarachnoid hemorrhage market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the aneurysmal subarachnoid hemorrhage market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current aneurysmal subarachnoid hemorrhage marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the aneurysmal subarachnoid hemorrhage market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the aneurysmal subarachnoid hemorrhage market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the aneurysmal subarachnoid hemorrhage market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of aneurysmal subarachnoid hemorrhage across the seven major markets?
• What is the number of prevalent cases (2018-2034) of aneurysmal subarachnoid hemorrhage by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of aneurysmal subarachnoid hemorrhage by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with aneurysmal subarachnoid hemorrhage across the seven major markets?
• What is the size of the aneurysmal subarachnoid hemorrhage patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of aneurysmal subarachnoid hemorrhage?
• What will be the growth rate of patients across the seven major markets?
   

Aneurysmal Subarachnoid Hemorrhage: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for aneurysmal subarachnoid hemorrhage drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the aneurysmal subarachnoid hemorrhage market?
• What are the key regulatory events related to the aneurysmal subarachnoid hemorrhage market?
• What is the structure of clinical trial landscape by status related to the aneurysmal subarachnoid hemorrhage market?
• What is the structure of clinical trial landscape by phase related to the aneurysmal subarachnoid hemorrhage market?
• What is the structure of clinical trial landscape by route of administration related to the aneurysmal subarachnoid hemorrhage market?